Hartford Business

Alexion inks $16.5M deal to develop neuro drug with Amsterdam startup

New Haven biotech Alexion Pharmaceuticals Inc. will partner with a startup in the Netherlands on a new drug to treat degenerative brain disorders. Alexion on Monday announced a deal with ...
Pharmabiz

Alexion to deliver 20 presentations across gMG, NF1 plexiform neurofibromas and neuromyelitis optica spectrum disorder at AAN meeting

Alexion to deliver 20 presentations across gMG, NF1 plexiform neurofibromas and neuromyelitis optica spectrum disorder at AAN meeting: Cambridge, UK Saturday, April 11, 2026, 18:0 ...
FierceBiotech

AstraZeneca's Alexion hopes to extend dominance in PNH as Big Pharma competitors close in

For years, Alexion has been the only name in the game for a blood disease called paroxysmal nocturnal hemoglobinuria (PNH). Now, a number of Big Pharmas want in, vying to show their candidates can go ...
MedCity News

AstraZeneca’s Rare Disease Pipeline Notches Another FDA Approval

An AstraZeneca drug acquired in a $930 million deal has received FDA approval as a treatment for a rare blood disorder. In this disease, paroxysmal nocturnal hemoglobinuria (PNH), a part of the immune ...
Business Wire

Alexion Joins NORD, EURORDIS and Other Patient Advocacy Groups in Supporting the Goals of Rare Disease Day 2011

Alexion's innovative approach to complement inhibition has received some of the pharmaceutical industry's highest honors: the 2008 Prix Galien USA Award for Best Biotechnology Product with broad ...